Expand GILD Menu
GILD MENU

GILD Latest Press Releases

-- February 24, 2025 --

European Medicines Agency Validates Gilead's Marketing Authorization Application and EU-Medicines for All Application for Twice-Yearly Lenacapavir for HIV Prevention Business Wire 8:30 AM

-- February 20, 2025 --

Gilead's Seladelpar Granted Conditional European Marketing Authorization for the Treatment of Primary Biliary Cholangitis Business Wire 4:30 PM

-- February 19, 2025 --

Gilead Sciences to Present at Upcoming Investor Conferences Business Wire 4:05 PM

-- February 18, 2025 --

U.S. FDA Accepts Gilead's New Drug Applications for Twice-Yearly Lenacapavir for HIV Prevention Under Priority Review Business Wire 8:30 AM

-- February 11, 2025 --

Gilead Sciences Announces 2.6 Percent Increase in First Quarter 2025 Dividend Business Wire 4:05 PM
Gilead Sciences Announces Fourth Quarter and Full Year 2024 Financial Results Business Wire 4:02 PM

-- January 30, 2025 --

Cognizant and Gilead Expand Partnership to Drive Greater Value Through Advanced Technology Applications PRNewswire 8:00 AM

-- January 28, 2025 --

Gilead Sciences to Release Fourth Quarter & Full Year 2024 Financial Results on Tuesday, February 11, 2025 Business Wire 4:05 PM

-- January 22, 2025 --

Demand for Advanced Pancreatic Cancer Treatments at All Time High as Promising Options Come into Focus Globe Newswire 8:30 AM

-- January 11, 2025 --

Gilead and LEO Pharma Enter Into Strategic Partnership to Accelerate Development of Oral STAT6 Program With Potential in Multiple Inflammatory Diseases Business Wire 11:00 AM

-- December 20, 2024 --

Gilead Sciences to Present at Upcoming Investor Conference Business Wire 4:05 PM

-- December 17, 2024 --

U.S. FDA Grants Breakthrough Therapy Designation to Trodelvy (sacituzumab govitecan-hziy) for Second-Line Treatment of Extensive-Stage Small Cell Lung Cancer Business Wire 8:30 AM
Gilead and Terray Therapeutics Announce Multi-Target Research Collaboration to Discover and Develop Novel Small Molecule Therapies Business Wire 7:00 AM

-- December 13, 2024 --

Gilead's Seladelpar Receives Positive CHMP Opinion for Primary Biliary Cholangitis Business Wire 6:37 AM

-- December 12, 2024 --

Gilead Sciences Appoints Dietmar Berger, MD, PhD, as Chief Medical Officer Business Wire 5:30 PM

-- December 9, 2024 --

Kite's Yescarta Only CAR T-Cell Therapy to Show Durable Response and Long-Term Survival After Five Years in Patients With Relapsed/Refractory Non-Hodgkin Lymphomas at ASH 2024 Business Wire 5:45 PM
Longest Follow-Up Data Reported for Kite's Tecartus CAR T-Cell Therapy at ASH 2024 Reinforce Durable Efficacy and Survival Benefits Business Wire 4:30 PM

-- December 8, 2024 --

Kite Presents New Data Underscoring Curative Potential of Yescarta in Relapsed/Refractory Large B-cell Lymphoma at ASH Business Wire 12:30 PM

-- December 3, 2024 --

Gilead and Tubulis Enter Into Exclusive Option and License Agreement to Develop ADC Candidate for Select Solid Tumor Target Business Wire 7:00 AM

-- November 27, 2024 --

Gilead Announces New England Journal of Medicine Publication of PURPOSE 2 Results Business Wire 5:00 PM

-- November 15, 2024 --

Gilead's Livdelzi (Seladelpar) Demonstrated a Sustained Efficacy and Long-Term Safety Profile in Management of Primary Biliary Cholangitis Business Wire 11:00 AM

-- November 13, 2024 --

Gilead Prices $3.5 Billion of Senior Unsecured Notes Business Wire 8:24 PM
Gilead Presents Full PURPOSE 2 Data Results for Twice-Yearly Lenacapavir for HIV Prevention at HIV Glasgow Business Wire 6:45 AM

-- November 12, 2024 --

Scientific Leadership Spotlighted as Gilead Presents Research Data Across Its Broad and Innovative HIV Treatment Portfolio and Pipeline Business Wire 5:30 AM

-- November 8, 2024 --

Gilead Sciences to Present at Upcoming Investor Engagements Business Wire 4:05 PM

-- November 7, 2024 --

Late-Breaking Clinical Data and Real-World Evidence Presented at HIV Glasgow as Gilead Extends Leadership Efforts Toward Ending the Epidemic Business Wire 8:30 AM

-- November 6, 2024 --

Gilead Sciences Announces Third Quarter 2024 Financial Results Business Wire 4:02 PM

-- November 5, 2024 --

Kite to Highlight Industry-Leading CAR T-Cell Therapy Portfolio at ASH 2024, Including Positive Survival Outcomes in Both Clinical Trials and the Real-World Business Wire 9:15 AM

-- October 22, 2024 --

Gilead to Present Latest Research Across Key Liver Disease Indication at the American Association for the Study of Liver Disease (AASLD) Meeting 2024 Business Wire 9:00 AM

-- October 19, 2024 --

Gilead and Merck Announce Phase 2 Data Showing a Treatment Switch to an Investigational Oral Once-Weekly Combination Regimen of Islatravir and Lenacapavir Maintained Viral Suppression in Adults at Week 48 Business Wire 5:09 PM

-- October 9, 2024 --

Gilead Sciences to Release Third Quarter 2024 Financial Results on Wednesday, November 6, 2024 Business Wire 4:05 PM
Gilead to Present Late-Breaking Data Highlighting Antiviral Portfolio, Innovative Research Pipeline and HIV Leadership at IDWeek 2024 Business Wire 8:30 AM

-- October 7, 2024 --

Gilead Presents Additional Efficacy, Safety and Demographic Data From PURPOSE 2 Trial at 5th HIV Research for Prevention Conference Business Wire 11:00 AM

-- October 2, 2024 --

Hetero Signs Voluntary Licensing Agreement with Gilead to Transform Global HIV response, Expanding Access to Groundbreaking Lenacapavir to 120 high-incidence countries PRNewswire 10:34 AM
Gilead Signs Royalty-Free Voluntary Licensing Agreements With Six Generic Manufacturers to Increase Access to Lenacapavir for HIV Prevention in High-Incidence, Resource-Limited Countries Business Wire 8:30 AM